Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CSTL · Nasdaq · United States · Services-Medical Laboratories
In shortCASTLE BIOSCIENCES INC is loss-making, generates cash and holds more cash than debt, with revenue growing (+3.7% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -12.4% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -7.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -5.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -7.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 5.26× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.02× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -497.79× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 6.15 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 8.2% | 53/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 22.2% | 29/100 |
| Operating margin volatility | 22.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 35.9% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 94 | 137 | 220 | 332 | 344 |
| Cost of revenue | 16 | 32 | 45 | 60 | 71 |
| Gross profit | 78 | 105 | 175 | 272 | 273 |
| Research & development | 30 | 45 | 54 | 52 | 52 |
| Selling, general & admin | 87 | 143 | 180 | 200 | 229 |
| Operating income | (40) | (73) | (68) | 8.7 | (43) |
| Interest expense | 0 | 0 | 0 | 0.6 | 0.1 |
| Income tax | (8.7) | (1.8) | 0.1 | 3.3 | (5.4) |
| Net income | (31) | (67) | (57) | 18 | (24) |
| Diluted EPS | −$1.24 | −$2.58 | −$2.14 | $0.62 | −$0.83 |
| Diluted shares (millions) | 25 | 26 | 27 | 29 | 29 |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
6.15 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 30, 2026